AstraZeneca boost as EU approves cancer drug
An AstraZeneca cancer drug received the green light by European regulators yesterday.
The London-listed drugs maker revealed that its bladder cancer treatment Imfinzi has been approved to treat adult patients in the European Union.
It comes amid reports that AstraZeneca – the FTSE 100’s largest company – is considering moving its listing from the UK to the US in what would be a hammer blow to London’s stock market.
The speculation was fuelled by the pharmaceutical sector’s growing frustration with the UK’s rules on approving medicines as well as a row over drug prices between the industry and the NHS.
Boost: AstraZeneca revealed that its bladder cancer treatment Imfinzi has been approved to treat adult patients in the European Union
Dave Fredrickson, head of AstraZeneca’s oncology haematology unit, said: ‘Imfinzi is poised to transform the standard of care for muscle-invasive bladder cancer in Europe.’
AstraZeneca shares edged up 1.3 per cent yesterday.
DIY INVESTING PLATFORMS
AJ Bell
AJ Bell
Easy investing and ready-made portfolios
Hargreaves Lansdown
Hargreaves Lansdown
Free fund dealing and investment ideas
interactive investor
interactive investor
Flat-fee investing from £4.99 per month
InvestEngine
InvestEngine
Account and trading fee-free ETF investing
Trading 212
Trading 212
Free share dealing and no account fee
Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.